Who are HyperAcute-Pancreas Immunotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyperacute-pancreas-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HyperAcute-Pancreas Immunotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HyperAcute-Pancreas Immunotherapy (HyperAcute-Pancreas Immunotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cancer immunotherapy vaccine combination. Area: Oncology.

phase 3 Cancer immunotherapy vaccine combination Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway Oncology Biologic Live · refreshed every 30 min

Target snapshot

HyperAcute-Pancreas Immunotherapy (HyperAcute-Pancreas Immunotherapy) — NewLink Genetics Corporation. HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HyperAcute-Pancreas Immunotherapy TARGET	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cancer immunotherapy vaccine combination class)

NewLink Genetics Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HyperAcute-Pancreas Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperacute-pancreas-immunotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing